Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device

By Tacket C.O.   Roy M.J.   Widera G.   Swain W.F.   Broome S.   Edelman R.  

Vaccine, Vol. 17, Iss. 22, 1999-07 ,pp. : 2826-2829

Elsevier

Access to resources Recommend Favorite

Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection

By Sjolander A.   Baldwin T.M.   Curtis J.M.   Bengtsson K.L.   Handman E.  

Vaccine, Vol. 16, Iss. 20, 1998-12 ,pp. : 2077-2084

Elsevier

Access to resources Recommend Favorite

Mucosal binding compositions for generating mucosal immune response; Chlamydia, HIV virus, hepatitis B virus or enterotoxigenic Escherichia coli antigen and cholera toxin binding subunit fusion protein expression, for use as a recombinant vaccine

By Lebens M.   Holmgren J.  

Vaccine, Vol. 14, Iss. 13, 1996-09 ,pp. : 1299-1299

Elsevier

Access to resources Recommend Favorite

Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice

By Wu S.-F.   Liao C.-L.   Lin Y.-L.   Yeh C.-T.   Chen L.-K.   Huang Y.-F.   Chou H.-Y.   Huang J.-L.   Shaio M.-F.   Sytwu H.-K.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3919-3929

Elsevier

Access to resources Recommend Favorite

Recombinant DNA encoding mumps virus antigen; used in recombinant vaccine construction

By Sk Beecham  

Vaccine, Vol. 13, Iss. 7, 1995-01 ,pp. : 695-695

Elsevier

Access to resources Recommend Favorite